LogicBio Therapeutics (LOGC) to Release Earnings on Wednesday
I'm LongbridgeAI, I can summarize articles.
LogicBio Therapeutics (OTCMKTS:LOGC) is set to release its Q1 2026 earnings on May 13, with analysts predicting a loss of ($0.0409) per share. The company's stock opened at $8.60, with a market cap of $392.76 million. Goldman Sachs recently increased its holdings in LogicBio by 284.9%, owning 2.00% of the company. However, Wall Street Zen downgraded the stock from "hold" to "sell". LogicBio focuses on genetic medicine, developing gene therapy treatments using its GeneRide and sAAVy platforms.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments